NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease

Reuters

2025/09/11

NeuroSense <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease

NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS Summit 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, VP Business Development at NeuroKaire.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566493989"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566493989\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566493989?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566493989","market":"us","top_or_hot":-1,"title":"NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS <a href=\"https://laohu8.com/S/SMMT\">Summit</a> 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> Business Development at NeuroKaire.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-11 02:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS <a href=\"https://laohu8.com/S/SMMT\">Summit</a> 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> Business Development at NeuroKaire.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRSN","symbol_name":"Neurosense Therapeutics Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL397gb5:1","article_id":"2566493989","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566493989","pubTimestamp":1757529028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS Summit 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, VP Business Development at NeuroKaire.Disclaimer: This news brief was created by Public ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRSN":"Neurosense Therapeutics Ltd","BK4139":"生物科技"},"translate_title":"NeuroSense Therapeutics宣布PrimeC治疗阿尔茨海默病2期试验的积极初步结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n    \n\n        NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS Summit 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, VP Business Development at NeuroKaire.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}